ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.32, $0.08 better than the analyst estimate of $1.24. Revenue for the quarter came in at $57.1 million versus the consensus estimate of $53.48 million.

For the fourth quarter 2018:

• Record net revenues of $57.1 million, an increase of 21% versus 2017
• GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46
• Adjusted non-GAAP EBITDA of $22.2 million
• Adjusted non-GAAP diluted earnings per share of $1.32

Arthur S. Przybyl, President and CEO, stated,

"ANI had a strong year, generating record net revenues, record adjusted non-GAAP EBITDA, and record adjusted non-GAAP diluted earnings per share. ANI's fourth quarter results also produced record net revenues, an increase of 21% over the prior year period, and record adjusted non-GAAP EBITDA, an increase of 13% of the prior year period. In 2018, adjusted non-GAAP EBITDA was 42% as a percent of net revenue and we generated $67.1 million of cash from operations during the year.

"Our record 2018 results exemplify ANI\'s role as a best-in-class specialty pharmaceutical company. We launched seven generic and four branded products during the year, increasing our commercial drug portfolio to 42 products. Our work has continued on our Cortrophin® re-commercialization project, and we intend to file the supplemental NDA in the first quarter of 2020. We continue to integrate our new Canadian operations and are working to use the facility for the tech transfer of several of our pipeline products and to grow our contract manufacturing business platform. With our new debt financing in place, we are in a strong position to not only refinance the convertible debt, but also have additional funds available to us for future acquisitions and provide ample opportunity to continue to grow."

GUIDANCE:

ANI Pharma sees FY2019 EPS of $5.57-$6.21, versus the consensus of $5.79. ANI Pharma sees FY2019 revenue of $231-245 million, versus the consensus of $243.37 million.

• Net revenues of $231 million to $245 million
• Adjusted non-GAAP EBITDA of $95 million to $105 million
• Adjusted non-GAAP diluted earnings per share of $5.57 to $6.21

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.